Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LILRB1 is an inhibitory receptor expressed on a variety of immune cells, including B cells, monocytes/macrophages, NK cells, and T cells. It binds to MHC class I molecules and delivers inhibitory signals via ITIMs in its cytoplasmic tail, dampening immune cell activation. LILRB1 plays a role in maintaining self-tolerance and is implicated in tumor immune evasion, making it a target for immune checkpoint blockade strategies.
Immune checkpoint inhibition via blockade of LILRB1-mediated suppression of immune cell activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1).